The persistent levels of S-IgG and S-IgA seropositivity, implies the vaccine’s effectiveness in inducing a robust and lasting immune response, but as these responses were more pronounced among individuals who were S-IgG seropositive at baseline, the role of prior infection or antigenic exposure is highlighted. This evidence concerns the gene CD79A and infection.